4.7 Article

MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis

期刊

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2016.03.025

关键词

Allergic rhinitis; conjunctivitis; Allergic Rhinitis and its Impact on Asthma; MACVIA-LR; information and communication technology; clinical decision support system

资金

  1. Actelion
  2. Almirall
  3. Meda
  4. Merck
  5. Merck Sharp Dohme
  6. Novartis
  7. Sanofi Aventis
  8. Takeda
  9. Teva
  10. Uriach
  11. AstraZeneca
  12. Chiesi
  13. GlaxoSmithKline
  14. OM Pharma
  15. Sanofi-Aventis
  16. Schering- Plough
  17. Research in Real Life
  18. Mundipharma
  19. ALK-Abello
  20. Allergopharma
  21. Allergy Therapeutics
  22. Anallergo
  23. Hal
  24. Lofarma
  25. Stallergenes
  26. Thermo Fisher
  27. Genentech
  28. Circassia and Biomay
  29. Boehringer Ingelheim
  30. Cipla
  31. Sanofi Pasteur MSD
  32. Boehringer Ingelheim International
  33. Stallergenes France
  34. Air Liquide Sante International
  35. Circassia
  36. ThermoFisher Scientific
  37. DBV
  38. Menarini
  39. MSD
  40. Napp
  41. Fundacao Ciencia e Tecnologia and Fundacao Calouste Gulbenkian
  42. Aerocrine
  43. Vitoria
  44. European Union project MeDALL
  45. European Union project iFAAM
  46. Adamed
  47. Pfizer
  48. Polpharma
  49. Lekam
  50. Bayer
  51. Celon Pharma
  52. FAES
  53. Sanofi
  54. UCB
  55. Senosiain
  56. Carnot
  57. Glenmark
  58. EU MedALL
  59. National and regional public funding applications
  60. Church Dwight
  61. Greer
  62. Johnson Johnson
  63. Mylan
  64. Regeneron/Sanofi
  65. Hartington Pharmaceuticals
  66. Pierre-Fabre
  67. Nestle
  68. Abbvie
  69. Amgen
  70. UK National Health Service
  71. British Lung Foundation
  72. AKL Ltd
  73. Respiratory Effectiveness Group
  74. Zentiva
  75. Kyorin
  76. SkyePharma
  77. Orion
  78. European Union Social Fund
  79. Lithuanian Ministry of Health
  80. European Academy of Pediatrics
  81. Microtest Dx
  82. Ansell
  83. Bayer Schering
  84. Fujisawa
  85. Henkel
  86. Kryolan
  87. Leti
  88. Procter Gamble
  89. Ranbaxy
  90. Schering Plough
  91. Asthma UK [MRC-Asthma UK Centre, MRC-AsthmaUKCentre] Funding Source: researchfish

向作者/读者索取更多资源

The selection of pharmacotherapy for patients with allergic rhinitis (AR) depends on several factors, including age, prominent symptoms, symptom severity, control of AR, patient preferences, and cost. Allergen exposure and the resulting symptoms vary, and treatment adjustment is required. Clinical decision support systems (CDSSs) might be beneficial for the assessment of disease control. CDSSs should be based on the best evidence and algorithms to aid patients and health care professionals to jointly determine treatment and its step-up or step-down strategy depending on AR control. Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR [fighting chronic diseases for active and healthy ageing]), one of the reference sites of the European Innovation Partnership on Active and Healthy Ageing, has initiated an allergy sentinel network (the MACVIA-ARIA Sentinel Network). A CDSS is currently being developed to optimize AR control. An algorithm developed by consensus is presented in this article. This algorithm should be confirmed by appropriate trials.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据